C B Falkson1, E T Vella2, E Yu3, M El-Mallah4, R Mackenzie2, P M Ellis5, Y C Ung6. 1. Radiation Oncology, Cancer Centre of Southeastern Ontario, Kingston General Hospital and Queen's University, Kingston. 2. Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton. 3. Radiation Oncology, London Regional Cancer Centre and Western University, London. 4. Radiation Oncology, Durham Regional Cancer Centre, Oshawa. 5. Medical Oncology, Juravinski Cancer Centre, and Department of Oncology, McMaster University, Hamilton; and. 6. Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.
Abstract
OBJECTIVES: For this guideline, we investigated the effectiveness of radiotherapy with curative intent in medically inoperable patients with early-stage non-small-cell lung cancer (nsclc). METHODS: The guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care and by the Lung Cancer Disease Site Group through a systematic review of mainly retrospective studies, expert consensus, and formal internal and external reviews. RECOMMENDATIONS: ■ Stereotactic body radiation therapy (sbrt) with curative intent is an option that should be considered for patients with early-stage, node-negative, medically inoperable nsclc. Qualifying Statements■ Because of the high dose per fraction, the planning process and treatment delivery for sbrt require the use of advanced technology to maintain an appropriate level of safety. Consistent patient positioning and 4-dimensional analysis of tumour and critical structure motion during simulation and treatment delivery are essential.■ Preliminary results for proton-beam therapy have been promising, but the technique requires further clinical study.■ Recommended fractionation schemes for sbrt should result in a biologically effective dose of 100 or greater by the linear quadric model, choosing an α/β value of 10 [bed10(LQ) ≥ 100]. Qualifying Statements■ Because of the increased risk of treatment-related adverse events associated with centrally located tumours, consideration of tumour size and proximity to critical central structures is required when determining the dose and fractionation.■ Examples of dose-fractionation schemes used in the included studies have been provided.■ Based on the current evidence and the opinion of the authors, radiation doses at bed10(LQ) greater than 146 might significantly increase toxicity and should be avoided.■ Determination of the radiation bed by the linear quadratic model has limitations for the extreme hypofractionated schemes used in sbrt.
OBJECTIVES: For this guideline, we investigated the effectiveness of radiotherapy with curative intent in medically inoperable patients with early-stage non-small-cell lung cancer (nsclc). METHODS: The guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care and by the Lung Cancer Disease Site Group through a systematic review of mainly retrospective studies, expert consensus, and formal internal and external reviews. RECOMMENDATIONS: ■ Stereotactic body radiation therapy (sbrt) with curative intent is an option that should be considered for patients with early-stage, node-negative, medically inoperable nsclc. Qualifying Statements■ Because of the high dose per fraction, the planning process and treatment delivery for sbrt require the use of advanced technology to maintain an appropriate level of safety. Consistent patient positioning and 4-dimensional analysis of tumour and critical structure motion during simulation and treatment delivery are essential.■ Preliminary results for proton-beam therapy have been promising, but the technique requires further clinical study.■ Recommended fractionation schemes for sbrt should result in a biologically effective dose of 100 or greater by the linear quadric model, choosing an α/β value of 10 [bed10(LQ) ≥ 100]. Qualifying Statements■ Because of the increased risk of treatment-related adverse events associated with centrally located tumours, consideration of tumour size and proximity to critical central structures is required when determining the dose and fractionation.■ Examples of dose-fractionation schemes used in the included studies have been provided.■ Based on the current evidence and the opinion of the authors, radiation doses at bed10(LQ) greater than 146 might significantly increase toxicity and should be avoided.■ Determination of the radiation bed by the linear quadratic model has limitations for the extreme hypofractionated schemes used in sbrt.
Entities:
Keywords:
Early-stage disease; clinical practice guidelines; inoperable tumours; non-small-cell lung cancer; stereotactic ablative radiation therapy; stereotactic body radiation therapy
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Larry Kestin; Inga Grills; Matthias Guckenberger; Jose Belderbos; Andrew J Hope; Maria Werner-Wasik; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Di Yan Journal: Radiother Oncol Date: 2014-03-11 Impact factor: 6.280
Authors: Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2012-09-11 Impact factor: 7.038
Authors: Osamu Suzuki; Takamasa Mitsuyoshi; Masayoshi Miyazaki; Teruki Teshima; Kinji Nishiyama; Jan F Ubbels; René A Bolt; Johannes A Langendijk; Joachim Widder Journal: Radiother Oncol Date: 2014-08-05 Impact factor: 6.280
Authors: Alexander Chi; Sijin Wen; Zhongxing Liao; Jack Fowler; Jiahong Xu; Nam P Nguyen; James S Welsh; Ritsuko Komaki Journal: Biomed Res Int Date: 2013-11-20 Impact factor: 3.411
Authors: Oren B Factor; Charles C Vu; Jeffrey G Schneider; Matthew R Witten; Scott L Schubach; Alicia E Gittleman; Donna T Catell; Jonathan A Haas Journal: Front Oncol Date: 2014-10-20 Impact factor: 6.244
Authors: John T Lucas; Jeffrey G Kuremsky; Mike Soike; William W Hinson; William T Kearns; Carnell J Hampton; A William Blackstock; James Urbanic Journal: Lung Cancer Date: 2014-04-28 Impact factor: 6.081
Authors: Andrea Bezjak; Rebecca Paulus; Laurie E Gaspar; Robert D Timmerman; William L Straube; William F Ryan; Yolanda I Garces; Anthony T Pu; Anurag K Singh; Gregory M Videtic; Ronald C McGarry; Puneeth Iyengar; Jason R Pantarotto; James J Urbanic; Alexander Y Sun; Megan E Daly; Inga S Grills; Paul Sperduto; Daniel P Normolle; Jeffrey D Bradley; Hak Choy Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: Juan Bayo; Tram Anh Tran; Lei Wang; Samuel Peña-Llopis; Amit K Das; Elisabeth D Martinez Journal: Cell Rep Date: 2018-10-23 Impact factor: 9.423